Get the Stockscreener App
0.6008
4.94%
-0.0312
After Hours:
.60
-0.0008
-0.13%
Tenaya Therapeutics Inc stock is traded at $0.6008, with a volume of 2.31M.
It is down -4.94% in the last 24 hours and up +46.14% over the past month.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
See More
Previous Close:
$0.632
Open:
$0.62
24h Volume:
2.31M
Relative Volume:
0.82
Market Cap:
$87.84M
Revenue:
-
Net Income/Loss:
$-111.13M
P/E Ratio:
-0.4552
EPS:
-1.32
Net Cash Flow:
$-91.53M
1W Performance:
+11.26%
1M Performance:
+46.14%
6M Performance:
-78.15%
1Y Performance:
-84.23%
1-Day Range:
$0.59
$0.6499
1-Week Range:
$0.55
$0.747
52-Week Range:
$0.36
$4.06
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.6008 | 87.84M | 0 | -111.13M | -91.53M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.06 | 113.97B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.84 | 52.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
304.67 | 40.16B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
586.76 | 35.45B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
276.53 | 27.94B | 3.81B | -644.79M | -669.77M | -6.24 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
Millennium Management LLC Sells 174,447 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) and Alpha Cognition (NASDAQ:ACOG) Critical Survey - Defense World
Squarepoint Ops LLC Decreases Stock Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Nuveen Asset Management LLC Buys 69,377 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Deutsche Bank AG Acquires 97,318 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Northern Trust Corp Grows Stock Holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics Appoints New Directors at Annual Meeting - TipRanks
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $6.25 Average Target Price from Brokerages - Defense World
Price T Rowe Associates Inc. MD Sells 2,892,201 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya therapeutics SVP Higa Tomohiro sells $615 in stock By Investing.com - Investing.com Nigeria
Tenaya Therapeutics chief medical officer sells $1,300 in stock By Investing.com - Investing.com Nigeria
Tenaya Therapeutics chief medical officer sells $1,300 in stock - Investing.com Australia
Tenaya therapeutics SVP Higa Tomohiro sells $615 in stock - Investing.com
Tenaya Therapeutics Awards Major Stock Options Package: 461K Shares for Strategic New Hires - Stock Titan
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Greenlane Renewables Announces First Quarter 2025 Financial Results - The Globe and Mail
Barclays PLC Sells 184,837 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics (TNYA) to Showcase Key Research at ASGCT 2025 | TNYA Stock News - GuruFocus
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting - The Manila Times
Tenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual Meeting - Nasdaq
Tenaya Therapeutics to Highlight Capsid Engineering, Gene - GlobeNewswire
Hsbc Holdings PLC Purchases New Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Equities Analysts Issue Forecasts for TNYA Q2 Earnings - Defense World
Tenaya Therapeutics’ (TNYA) Buy Rating Reiterated at Chardan Capital - Defense World
We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate - Yahoo Finance
Chardan Capital Maintains Buy Rating for Tenaya Therapeutics (TNYA) | TNYA Stock News - GuruFocus
Tenaya Therapeutics Reports Q1 2025 Financial Results - TipRanks
Tenaya (TNYA) Reports Promising Clinical Trial Developments and Financial Outlook | TNYA Stock News - GuruFocus
Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
A Cautious Investment in the Drone Sector - The Globe and Mail
Geode Capital Management LLC Sells 27,419 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Why To Invest In Tenaya Therapeutics Inc (NASDAQ: TNYA) Stock? - Marketing Sentinel
H.C. Wainwright maintains Buy on Tenaya Therapeutics stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Tenaya Therapeutics stock - Investing.com Australia
TNYATenaya Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Tenaya reports progress in ARVC gene therapy study - Investing.com
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025 - The Manila Times
Tenaya Therapeutics Presents Interim Data from RIDGE™ - GlobeNewswire
Major Breakthrough: 175-Patient ARVC Study Shows 93% Could Benefit from New Gene Therapy Treatment - Stock Titan
Strategy (MSTR) Buys Another $556 Million Worth of Bitcoin - The Globe and Mail
Tenaya Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com India
Tenaya Therapeutics faces Nasdaq delisting over share price - Investing.com Australia
Alignment Healthcare to Announce First Quarter 2025 Financial Results and Host Conference Call Thursday, May 1, 2025 - The Globe and Mail
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.12%
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):